

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-38890

**Cortexyme, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**269 East Grand Ave.**

**South San Francisco, California**

(Address of principal executive offices)

**90-1024039**

(I.R.S. Employer  
Identification No.)

**94080**

(Zip Code)

Registrant's telephone number, including area code: (415) 910-5717

Securities registered pursuant to Section 12(b) of the Act:

**Title of each class**

Common Stock, par value \$0.001 per share

**Trading  
Symbol(s)**

CRTX

**Name of each exchange on which registered**

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 12, 2019, the registrant had 26,852,483 shares of common stock, \$0.001 par value per share, outstanding.

## Table of Contents

	<u>Page</u>
<b>PART I.</b>	<b><u>FINANCIAL INFORMATION</u></b>
Item 1.	<u>Financial Statements (Unaudited)</u> 1
	<u>Condensed Balance Sheets</u> 1
	<u>Condensed Statements of Operations and Comprehensive Loss</u> 2
	<u>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity / (Deficit)</u> 3
	<u>Condensed Statements of Cash Flows</u> 5
	<u>Notes to Unaudited Condensed Financial Statements</u> 6
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 15
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 21
Item 4.	<u>Controls and Procedures</u> 22
<b>PART II.</b>	<b><u>OTHER INFORMATION</u></b>
Item 1.	<u>Legal Proceedings</u> 23
Item 1A.	<u>Risk Factors</u> 23
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u> 23
Item 3.	<u>Defaults Upon Senior Securities</u> 23
Item 4.	<u>Mine Safety Disclosures</u> 23
Item 5.	<u>Other Information</u> 23
Item 6.	<u>Exhibits</u> 24
	<u>Signatures</u> 25

## Item 1. Financial Statements.

Cortexyme, Inc.  
Condensed Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

	September 30, 2019	December 31, 2018 (1)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 44,740	\$ 24,872
Short term investments	75,730	46,844
Restricted cash	250	—
Prepaid expenses and other current assets	3,649	868
Total current assets	124,369	72,584
Property and equipment, net	270	283
Right-of-use assets	1,171	—
Long term investments	7,341	—
Other assets	263	10
Total assets	\$ 133,414	\$ 72,877
<b>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY / (DEFICIT)</b>		
Current liabilities:		
Accounts Payable	\$ 2,295	\$ 495
Accrued expenses and other current liabilities	3,832	962
Total current liabilities	6,127	1,457
Total liabilities	6,127	1,457
Commitments and contingencies		
Series A redeemable convertible preferred stock, par value \$0.001, no shares authorized, issued and outstanding as of September 30, 2019 and 9,008,931 shares authorized, 9,008,919 shares issued and outstanding December 31, 2018; liquidation preference of \$0 and \$17,178 at September 30, 2019 and December 31, 2018, respectively	—	17,178
Series B redeemable convertible preferred stock, par value \$0.001, no shares authorized, issued and outstanding as of September 30, 2019 and 9,430,145 shares authorized, 9,152,108 shares issued and outstanding as December 31, 2018; liquidation preference of \$0 and \$87,972 at September 30, 2019 and December 31, 2018, respectively	—	86,868
Stockholders' deficit:		
Preferred Stock, \$0.001 par value, 10,000,000 authorized, no shares issued and outstanding September 30, 2019 and no shares authorized, issued and outstanding at December 31, 2018	—	—
Common stock, \$0.001 par value, 100,000,000 and 24,794,114 shares authorized, 26,841,149 and 3,412,366 issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	27	3
Additional paid in capital	184,590	245
Accumulated other comprehensive income (loss)	96	(49)
Accumulated deficit	(57,426)	(32,825)
Total stockholders' equity / (deficit)	127,287	(32,626)
Total liabilities, redeemable convertible preferred stock and stockholders' equity / (deficit)	\$ 133,414	\$ 72,877

(1) The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date

The accompanying notes are an integral part of these condensed financial statements.

**Cortexyme, Inc.**  
**Condensed Statements of Operations and Comprehensive Loss**  
(Unaudited)  
(In thousands, except share and per share amounts)

	<u>Three Months Ended September 30,</u>		<u>Nine Months Ended September 30,</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Operating expenses:				
Research and development	\$ 8,253	\$ 2,290	\$ 20,187	\$ 6,989
General and administrative	2,316	584	6,032	1,288
Total operating expenses	<u>10,569</u>	<u>2,874</u>	<u>26,219</u>	<u>8,277</u>
Loss from operations	(10,569)	(2,874)	(26,219)	(8,277)
Interest income	711	353	1,618	434
Interest expense	—	—	—	(957)
Change in fair value of derivative liability	—	—	—	(206)
Net loss	<u>(9,858)</u>	<u>(2,521)</u>	<u>(24,601)</u>	<u>(9,006)</u>
Other comprehensive income/ (loss):				
Unrealized gain / (loss) on available for sales securities	16	(16)	145	(16)
Total comprehensive income/(loss)	<u>(9,842)</u>	<u>(2,537)</u>	<u>(24,456)</u>	<u>(9,022)</u>
Net loss per share - basic and diluted	<u>(0.37)</u>	<u>(0.75)</u>	<u>(1.59)</u>	<u>(2.68)</u>
Weighted average shares of common stock outstanding - basic and diluted	<u>26,841,149</u>	<u>3,361,029</u>	<u>15,489,216</u>	<u>3,360,683</u>

The accompanying notes are an integral part of these condensed financial statements.

**Cortexyme, Inc.**  
**Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity / (Deficit)**  
(Unaudited)  
(In thousands, except share and per share amounts)

For the three months ended September 30, 2019 and 2018										
	Series A Redeemable Convertible Preferred Stock		Series B Redeemable Convertible Preferred Stock		Common Stock		Additional Paid in Capital	Other Comprehensive Income / (Loss)	Accumulated Deficit	Shareholders' Equity/ (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount				
<b>Balance June 30, 2019</b>	—	\$ —	—	\$ —	26,841,149	\$ 27	\$ 183,678	\$ 80	\$ (47,568)	\$ 136,217
Exercise of stock options	—	—	—	—	—	—	—	—	—	—
Stock based compensation	—	—	—	—	—	—	912	—	—	912
Other comprehensive income	—	—	—	—	—	—	—	16	—	16
Net loss	—	—	—	—	—	—	—	—	\$ (9,858)	(9,858)
<b>Balance September 30, 2019</b>	—	\$ —	—	\$ —	26,841,149	\$ 27	\$ 184,590	\$ 96	\$ (57,426)	\$ 127,287
<b>Balance June 30, 2018</b>	9,008,919	\$ 17,178	9,037,671	86,715	3,361,016	\$ 3	\$ 93	—	\$ (26,834)	\$ (26,738)
Stock based compensation	—	—	—	—	—	—	20	—	—	20
Vesting of Series B redeemable convertible preferred stock in lieu of rent	—	—	—	61	—	—	—	—	—	—
Issuance of Series B redeemable convertible preferred stock in connection with the facility lease agreement	—	—	114,437	—	—	—	—	—	—	—
Other comprehensive loss	—	—	—	—	—	—	—	(16)	—	(16)
Net loss	—	—	—	—	—	—	—	—	(2,521)	(2,521)
<b>Balance September 30, 2018</b>	9,008,919	\$ 17,178	9,152,108	\$ 86,776	3,361,016	\$ 3	\$ 113	\$ (16)	\$ (29,355)	\$ (29,255)

The accompanying notes are an integral part of these condensed financial statements.

**Cortexyme, Inc.**  
**Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity/ (Deficit) (continued)**  
(Unaudited)

(In thousands, except share and per share amounts)

	For the nine months ended September 30, 2019 and 2018									
	Series A Redeemable Convertible Preferred Stock		Series B Redeemable Convertible Preferred Stock		Common Stock		Additional Paid in Capital	Other Comprehensive Income / (Loss)	Accumulated Deficit	Shareholders' Equity / (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount				
<b>Balance January 1, 2019</b>	9,008,919	\$ 17,178	9,152,108	\$ 86,868	3,412,366	\$ 3	\$ 245	\$ (49)	\$ (32,825)	\$ (32,626)
Exercise of stock options	—	—	—	—	166,015	1	68	—	—	69
Stock based compensation	—	—	—	—	—	—	1,479	—	—	1,479
Vesting of Series B redeemable convertible preferred stock in lieu of rent	—	—	—	948	—	—	—	—	—	—
Conversion of redeemable convertible preferred stock to common stock	(9,008,919)	(17,178)	(9,152,108)	(87,816)	18,161,027	18	104,976	—	—	104,994
Initial public offering of common stock, net of issuance costs	—	—	—	—	5,073,800	5	77,822	—	—	77,827
Exercise of stock warrant	—	—	—	—	27,941	—	—	—	—	—
Other comprehensive income	—	—	—	—	—	—	—	145	—	145
Net loss	—	—	—	—	—	—	—	—	(24,601)	(24,601)
<b>Balance September 30, 2019</b>	—	\$ —	—	\$ —	26,841,149	\$ 27	\$ 184,590	\$ 96	\$ (57,426)	\$ 127,287
<b>Balance January 1, 2018</b>	9,008,919	\$ 17,178	—	\$ —	3,361,016	\$ 3	\$ 66	\$ —	\$ (20,349)	\$ (20,280)
Stock based compensation	—	—	—	—	—	—	47	—	—	47
Proceeds from Series B redeemable convertible preferred stock, net of issuance costs	—	—	7,890,466	75,688	—	—	—	—	—	—
Issuance of Series B redeemable convertible preferred stock in connection with the conversion of convertible promissory notes and accrued interest	—	—	1,147,205	11,027	—	—	—	—	—	—
Vesting of Series B redeemable convertible preferred stock in lieu of rent	—	—	—	61	—	—	—	—	—	—
Issuance of Series B redeemable convertible preferred stock in connection with the facility lease agreement	—	—	114,437	—	—	—	—	—	—	—
Other comprehensive loss	—	—	—	—	—	—	—	(16)	—	(16)
Net loss	—	—	—	—	—	—	—	—	(9,006)	(9,006)
<b>Balance September 30, 2018</b>	9,008,919	\$ 17,178	9,152,108	\$ 86,776	3,361,016	\$ 3	\$ 113	\$ (16)	\$ (29,355)	\$ (29,255)

The accompanying notes are an integral part of these condensed financial statements.

**Cortexyme, Inc.**  
**Condensed Statements of Cash Flows**  
(Unaudited)

	<b>For the Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
Cash flows from operating activities		
Net Loss	\$ (24,601)	\$ (9,006)
Adjustments to reconcile net loss to net cash used in operating activities:		
Non-cash interest expense related to convertible promissory notes	—	262
Non-cash rent expense	275	61
Stock based compensation	1,479	47
Depreciation and amortization	112	27
Accretion of discount on convertible promissory notes payable	—	694
Amortization of discount on available for sale investments	(728)	(122)
Change in fair value of derivative liability	—	206
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	(3,281)	20
Other assets	(253)	—
Accounts payable	1,800	50
Accrued expenses and other current liabilities	2,870	39
Net cash used in operating activities	<u>(22,327)</u>	<u>(7,722)</u>
Cash flow from investing activities:		
Purchase of investments	(98,475)	(48,103)
Proceeds from maturities of investments	63,070	—
Purchase of property and equipment	(46)	(212)
Net cash used in investing activities	<u>(35,451)</u>	<u>(48,315)</u>
Cash flows from financing activities:		
Proceeds from issuance of convertible promissory note payable	—	250
Proceeds from issuance of commons stock upon exercise of stock options	69	—
Proceeds from Series B redeemable convertible preferred stock	—	75,688
Proceeds from initial public offering, net of stock offering costs	77,827	—
Net cash provided by financing activities	<u>77,896</u>	<u>75,938</u>
Net increase in cash, cash equivalents and restricted cash	20,118	19,901
Cash, cash equivalents and restricted cash at beginning of period	24,872	7,393
Cash, cash equivalents and restricted cash at end of period	<u>\$ 44,990</u>	<u>\$ 27,294</u>
Supplemental disclosures of non-cash information:		
Right-of-use assets obtained in exchange for new operating lease liabilities	<u>\$ 878</u>	<u>\$ —</u>
Right-of-use assets obtained in exchange for new finance lease liabilities	<u>\$ 500</u>	<u>\$ —</u>
Conversion of Series A redeemable convertible preferred stock to common stock on initial public offering	<u>\$ 17,178</u>	<u>\$ —</u>
Conversion of Series B redeemable convertible preferred stock to common stock on initial public offering	<u>\$ 87,816</u>	<u>\$ —</u>
Acceleration of vesting of Series B redeemable convertible preferred stock on initial public offering	<u>\$ 856</u>	<u>\$ —</u>
Issuance of Series B redeemable convertible preferred stock in connection with conversion of convertible promissory notes and accrued interest	<u>\$ —</u>	<u>\$ 11,027</u>
Issuance of Series B redeemable convertible stock for facility lease	<u>\$ —</u>	<u>\$ 1,100</u>

The accompanying notes are an integral part of these condensed financial statements.

**Cortexyme, Inc.**  
**Notes to Unaudited Condensed Financial Statements**

**Note 1. Organization**

***Description of Business***

Cortexyme, Inc. (the “Company”) was incorporated in the State of Delaware in June 2012 and is headquartered in South San Francisco, California. The Company is a clinical stage biopharmaceutical company focused on developing therapeutics based on data supporting a new theory of the cause of Alzheimer’s disease and other degenerative disorders. Cortexyme is targeting a specific, infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models.

***Reverse Stock Split***

On April 25, 2019, the Company’s Board of Directors approved a one-for-0.367647 reverse split of the Company’s issued and outstanding common stock, redeemable convertible preferred stock, and stock options. The par value of the common stock was not adjusted as a result of the reverse stock split. All share and per share amounts in the accompanying unaudited condensed financial statements and notes to the unaudited condensed financial statements have been retroactively adjusted for all periods presented to reflect the reverse stock split.

***Initial Public Offering***

On May 8, 2019, the Company’s registration statement on Form S-1 (File No. 333-230853) for its initial public offering of common stock (“IPO”) was declared effective by the Securities and Exchange Commission (“SEC”). On May 13, 2019, the Company closed its IPO with the sale of 5,073,800 shares of common stock, which included 661,800 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of \$17.00 per share, resulting in net proceeds of \$77.8 million, after deducting underwriting discounts and commissions and estimated offering expenses paid by the Company.

In addition, in connection with the closing of the IPO, all of the Company’s outstanding shares of redeemable convertible preferred stock were automatically converted into 18,161,027 shares of common stock, and there are no shares of redeemable convertible preferred stock outstanding.

***Liquidity and Capital Resources***

The Company has incurred losses and negative cash flows from operations since inception and expects to continue to generate operating losses for the foreseeable future. As of September 30, 2019, the Company had an accumulated deficit of \$57.4 million. Since inception through September 30, 2019, the Company has funded operations primarily with the net proceeds from the issuance of convertible promissory notes, from the issuance of redeemable convertible preferred stock and from the net proceeds from the IPO. As of September 30, 2019, the Company had cash, cash equivalents, and short-term investments of \$120.5 million, which it believes will be sufficient to fund its planned operations for a period of at least 12 months from the date of the issuance of the accompanying unaudited financial statements.

Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may need to raise additional capital to fully implement its business plan. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidate.

**Note 2. Summary of Significant Accounting Policies**

***Basis of Presentation***

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.



The condensed balance sheet as of September 30, 2019, the condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2019 and 2018, the condensed statements of stockholders' equity/(deficit) as of September 30, 2019 and 2018, the condensed statements of cash flows for the nine months ended September 30, 2019 and 2018, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company's final prospectus (the "Prospectus") filed with the SEC on May 9, 2019. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019, or for any other future annual or interim period.

### ***Use of Estimates***

The preparation of the Company's financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's financial statements relate to the determination of the fair value of common stock prior to the initial public offering, stock-based awards and other issuances, valuation of derivative instruments, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company's estimates.

### ***Significant Accounting Policies***

There have been no significant changes to the accounting policies during the nine months ended September 30, 2019, as compared to the significant accounting policies described in the Prospectus.

### ***Cash, Cash Equivalents, and Restricted Cash***

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the periods presented.

Restricted cash as of September 30, 2019 relates to a compensating balance to secure a credit card facility.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed balance sheets that sum to the total of the same amounts shown in the condensed statements of cash flows (in thousands):

	<b>Nine Months Ended September 30,</b>	
	<b>2019</b>	<b>2018</b>
Cash and cash equivalents	\$ 44,740	\$ 27,294
Restricted cash	250	—
<b>Total cash, cash equivalents and restricted cash</b>	<b>\$ 44,990</b>	<b>\$ 27,294</b>

## ***Fair Value Measurements***

The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;

Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;

Level 3 - Inputs that are unobservable. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period.

## ***Leases***

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update, or ASU, No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2019.

The Company determines if an arrangement includes a lease at inception. Right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The right-of-use asset includes any lease payments made and excludes lease incentives. Incremental borrowing rate is used in determining the present value of future payments. The Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The lease terms may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the non-cancelable lease term. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company’s historical accounting under previous lease guidance, ASC 840, Leases (Topic 840).

## ***Emerging Growth Company Status***

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to not use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies.

## ***Recent Accounting Pronouncements adopted***

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This ASU requires that substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for interim and annual periods beginning after December 15, 2018. Additionally, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2019 and as a result, recorded a right-of-use asset of \$0.9 million, a short-term lease liability of \$0.3 million, and a long-term lease liability of \$0.6 million and no cumulative effect adjustment was made to the retained earnings as of the adoption date. The Company also elected the package of practical expedients under the transition guidance that will retain the historical lease classification and initial direct costs for any leases that exist prior to adoption of the new guidance and the practical expedient to not separate lease and nonlease components. See Note 5 for further disclosure.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Part I applies to entities that issue financial instruments such as warrants, convertible debt or redeemable convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public entities, ASU 2017-11 is required to be adopted for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2017-11 did not have any impact on the Company’s financial statements since the Company did not have any instruments subject to the scope of the ASU.

***Recent accounting pronouncements not yet adopted***

The following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:

**Fair Value Measurement—Disclosure Framework:** In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance changes disclosure requirements related to fair value measurements as part of the disclosure framework project. The disclosure framework project aims to improve the effectiveness of disclosures in the notes to the financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. This guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company does not believe this pronouncement will have a material impact on its financial statements or disclosures.

**Financial Instruments—Credit Losses:** In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the principles around the recognition of credit losses by mandating entities incorporate an estimate of current expected credit losses when determining the value of certain assets. The guidance also amends reporting around allowances for credit losses on available-for-sale marketable securities. This guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.

In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles – Goodwill and other – Internal-Use Software (Subtopic 350-40), which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company does not believe this pronouncement will have a material impact on its financial statements or disclosures.

**Note 3. Fair Value Measurements**

The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.

Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September 30, 2019 and December 31, 2018 are presented in the following tables (in thousands):

	Fair Value Measurements at September 30, 2019				
	Fair Value Hierarchy	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Money market funds	Level 1	\$ 20,980	\$ —	\$ —	\$ 20,980
Certificates of Deposit	Level 2	20,611	62	—	20,673
Repurchase Agreements	Level 2	15,000	—	—	15,000
Corporate notes	Level 2	15,183	1	(11)	15,173
U.S. government notes	Level 2	51,382	44	—	51,426
Total cash equivalents and investments		<u>\$ 123,156</u>	<u>\$ 107</u>	<u>\$ (11)</u>	<u>\$ 123,252</u>

Classified as:

Cash equivalents	\$ 40,181
Short-term investments	75,730
Long-term investments	7,341
Total cash equivalents and investments	<u>\$ 123,252</u>

	Fair Value Measurements at December 31, 2018				
	Fair Value Hierarchy	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Money market funds	Level 1	\$ 11,815	\$ —	\$ —	\$ 11,815
Commercial paper	Level 2	14,362	—	(2)	14,360
Corporate notes	Level 2	16,129	—	(18)	16,111
U.S. government notes	Level 2	8,980	—	(1)	8,979
Asset backed securities	Level 2	9,220	—	(28)	9,192
Total cash equivalents and investments		<u>\$ 60,506</u>	<u>\$ —</u>	<u>\$ (49)</u>	<u>\$ 60,457</u>

Classified as:

Cash equivalents	\$ 13,613
Short-term investments	46,844
Total cash equivalents and investments	<u>\$ 60,457</u>

As of September 30, 2019, the remaining contractual maturities of available-for-sale securities was approximately three months. There have been no significant realized losses on available-for-sale securities for the period presented. Based on the Company's review of its available-for-sale securities, the Company believes it had no other-than-temporary impairments on these securities as of September 30, 2019, because the Company does not intend to sell these securities nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis.

For the three and nine months ended September 30, 2018, the Company realized \$0 and \$206,000 of expenses, respectively, for a redemption premium feature accounted for as embedded derivative liability in accordance with ASC 815. The derivative liability is revalued at the end of each reporting period and any change in fair value is recognized in "Change in fair value of redemption premium liability" in the Statement of Operations. This liability was extinguished in May 2018 with the Series B redeemable preferred stock financing.

There were no transfers between Levels 1, 2 or 3 for the period presented.

#### Note 4. Balance Sheet Components

##### Prepaid expenses and Other Current Assets

Prepaid expenses and Other Current Assets consist of the following (in thousands):

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Prepaid expenses	\$ 136	\$ 47
Prepaid Insurance	1,433	—
Prepaid clinical trial expenses	1,179	587
Prepaid drug manufacturing	39	—
Prepaid research and development expenses	350	166
Other assets	512	68
Total prepaid expenses and other current assets	<u>\$ 3,649</u>	<u>\$ 868</u>

##### Property and Equipment

Property and Equipment consist of the following (in thousands):

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Lab Equipment	\$ 424	\$ 378
Less: accumulated depreciation	(154)	(95)
Property and equipment, net	<u>\$ 270</u>	<u>\$ 283</u>

##### Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Personnel expenses	\$ 679	\$ 483
Professional fees	98	75
Clinical trial expenses	2,251	—
Drug manufacturing expenses	403	—
Research and development expenses	386	380
Other	15	24
Total accrued liabilities	<u>\$ 3,832</u>	<u>\$ 962</u>

#### Note 5. Leases

As described in “Note 2 Summary of Significant Accounting Policies,” the Company adopted Topic 842 as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with historic accounting under Topic 840.

##### Real Estate Operating Leases

In June 2018, the Company entered into a three-year lease agreement with no renewal options with a related party, one of the investors in the Series B redeemable convertible preferred stock. The lease began on July 16, 2018 and provides 3,185 square feet of office and laboratory space in South San Francisco, California. The Company issued 114,437 shares of its Series B redeemable convertible preferred stock with a fair value of \$1.1 million in exchange for the leased facility. No other payments are due under the lease. The common area maintenance and other operating costs are included in the base rent. 100% of the issued shares were initially subject to a repurchase option. Pursuant to the terms of the lease, each month beginning on the one-month anniversary of the commencement date of the lease, 1/36<sup>th</sup> of the total shares are released from the repurchase option until all shares are released over the lease period of three years. The scheduled release of shares ceased immediately upon the IPO which was a terminating event.

The Company completed its IPO on May 13, 2019 and as a result, pursuant to the terms of the lease agreement, all previously unvested shares were fully vested and as part of the IPO process, all outstanding shares of the Company's redeemable convertible preferred stock including the Series B redeemable convertible preferred stock issued in connection with the lease agreement were converted into shares of the Company's common stock on a 1-for-1 basis and the operating lease liability was extinguished.

In May 2019 the Company entered into an amendment to the lease agreement to rent additional space in the same facility under the same terms as its existing facility lease except the terms of payment. Under the terms of the amendment, the Company paid a one-time fee of approximately \$63,000 for the additional space and the lease agreement will terminate in July 2021. No other payments are due under the lease agreement and no renewal option is available. As the entire lease is prepaid, there is no associated lease liability.

The Company recognizes lease expense on a straight-line basis over the term of its operating lease. As of September 30, 2019, future rent expense of \$723,000 will be recognized over the remaining term of 22 months on a straight-line basis over the respective lease period. Rent expense for the operating lease for the three months and nine months ended September 30, 2019 was \$103,000 and \$287,000 respectively.

#### **Clinical Equipment Financing Lease**

During the second quarter, the Company began using certain vendor supplied equipment in connection with its on-going clinical trial. The Company analyzed the agreements and determined that they contained embedded leases. Under the agreements, the Company has prepaid for the use of the equipment through the initial lease term of approximately three years. As a result, the Company has no lease liability associated with these right of use assets. The Company recognizes the lease expense in research and development expenses in the statement of operations and recognizes expense on a straight-line basis starting when the equipment is placed into service until the end of the contract term. Equipment placed into service is amortized into expense over periods ranging from 28 to 34 months. Amortization expense of the financing lease right of use asset for the three and nine months ended September 30, 2019 was \$38,000 and \$53,000 respectively.

Operating and finance lease right of use asset amounts consist of the following as of September 30, 2019:

Right of use assets- operating lease	\$	724
Right of use assets- financing lease		500
Less: accumulated depreciation		(53)
Total right of use assets	<u>\$</u>	<u>1,171</u>

The Company determined its operating and finance lease liabilities for operating lease using a discount rate of 4.00% based on the rate that the Company would have to pay to borrow on a collateralized basis for a similar lease an amount equal to the lease payments in a similar economic environment. As of September 30, 2019, the weighted-average remaining lease term for the operating leases was 1.8 years. The weighted-average remaining lease term for the finance leases was 2.25 years.

#### **Note 6. Stock-Based Compensation**

On December 4, 2014, the Company's stockholders approved the 2014 Stock Plan ("2014 Plan") and amended the 2014 Plan on April 25, 2019. The 2014 Plan was amended, restated and re-named the 2019 Equity Incentive Plan (the "2019 Plan"), which became effective as of May 7, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2014 Plan were added to the shares reserved for issuance under the 2019 Plan.

The 2019 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Company's employees, directors, and consultants. The maximum aggregate number of shares that may be issued under the 2019 Plan is 5,131,549 shares of the Company's common stock. In addition, the number of shares available for issuance under the 2019 Plan will be annually increased on the first day of each of its fiscal years beginning with fiscal 2020, by an amount equal to the least of (i) 2,146,354 shares of common stock; (ii) 4% of the outstanding shares of its common stock as of the last day of its immediately preceding fiscal year; and (iii) such other amount as the Company's Board of Directors may determine.

The 2019 Plan may be amended, suspended or terminated by the Company's Board of Directors at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2019 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company's Board of Directors, the 2019 Plan will automatically terminate on April 23, 2029.

As of September 30, 2019, the Company had 2,439,782 shares available for future issuance under the 2019 Plan.

For the three months and nine months ended September 30, 2019, the Company recognized \$912,000 and \$1,479,000 of stock-based compensation expense, respectively related to options granted to employees and non-employees. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statement of operations for stock-based compensation arrangements.

	Number of Options and Unvested Shares	Weighted Average Exercise Price	Weighted average remaining contractual life (years)	Aggregate intrinsic value
Balance at December 31, 2018	1,885,504	1.57	9.07	\$ 1,252,496
Options granted	912,637	15.60		
Options exercised	(166,015)	0.41		
Options cancelled	(209,931)	20.36		
Balance at September 30, 2019	<u>2,422,195</u>	5.30	8.85	48,115,831
Options vested and expected to vest as of September 30, 2019	<u>2,422,195</u>	5.30	8.85	48,115,831
Options exercisable as of September 30, 2019	<u>551,003</u>	2.16	7.91	\$ 12,626,200

The total unrecognized share-based compensation cost at September 30, 2019 amounted to approximately \$7,013,000 which is expected to be recognized over the next 3 years.

### **Employee Stock Purchase Plan**

On April 24, 2019, the Company's Board of Directors adopted its 2019 Employee Stock Purchase Plan ("2019 ESPP"), which was subsequently approved by the Company's stockholders and became effective on May 7, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the Internal Revenue Code (the "Code") for U.S. employees. In addition, the 2019 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 268,295 shares of common stock for issuance under the 2019 ESPP. In addition, the number of shares reserved for issuance under the 2019 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the least of: (i) 536,589 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company's Board of Directors. The 2019 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company's common stock on specified dates during such offerings. The administrator has not yet approved an offering under the 2019 ESPP.

### **Note 7. Related Party Transactions**

In June 2014, the Company entered into a research grant and license agreement (the Agreement) with a stockholder of the Company. The Agreement requires the Company to pay royalties to the stockholder in the amount of 3% of gross revenues not to exceed \$1.05 million. This agreement was amended in April 2019 and the royalty payment provision was removed.

As described in Note 5, the Company entered into a three-year lease agreement with a Series B redeemable preferred stock investor. The lease began on July 16, 2018 and provides 3,185 square feet of office space in South San Francisco, California. The Company issued 114,437 restricted shares of its Series B redeemable convertible preferred stock in exchange for the use of the leased facility. In May 2019, the Company entered into an amendment to the lease agreement to rent additional space in the same building for a one-time payment of approximately \$63,000 on the same terms as the July 2018 agreement except rent.

As described in Note 1, the Company completed its IPO in May 2019. As a result of the IPO, in addition to the 229,453 shares of Series B redeemable convertible preferred stock held by the investor, an additional 82,649 shares of the Company's Series B redeemable convertible preferred stock under issued pursuant the lease agreement fully vested and were converted into common stock of the Company on a one-to-one basis.

**Note 8. Income Taxes**

The Company has a history of losses and expects to record a loss in 2019.

The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

A valuation allowance is provided for significant deferred tax assets when it is more likely than not that such assets will not be realized through future operations. No provision for income taxes has been recorded due to the available net operating loss carry forwards. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the future deferred tax assets.

**Note 9. Net Loss Per Share**

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:

	September 30,	
	2019	2018
Series A redeemable convertible preferred stock	—	9,008,919
Series B redeemable convertible preferred stock	—	9,152,108
Warrants	—	27,941
Options issued and outstanding	2,422,195	928,944
Total	<u>2,422,195</u>	<u>19,117,912</u>

**Note 10. Subsequent Events**

The Company has completed an evaluation of all subsequent events through the date these financial were issued. Based on its evaluation, there were no subsequent events to report.



## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis and the unaudited interim condensed financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2018 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our final prospectus filed with the Securities and Exchange Commission, or SEC, on May 9, 2019 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, which we refer to as our Prospectus. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “Cortexyme,” “we,” “us” and “our” refer to Cortexyme, Inc. In preparing the Management’s Discussion and Analysis below, we presume the readers have access to and have read the Management’s Discussion and Analysis in our Prospectus, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part II, Item 1A -“Risk Factors,” and elsewhere in this Quarterly Report on Form 10-Q. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

### Overview

We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Our approach is based on the seminal discovery of the presence of *Porphyromonas gingivalis*, or *P. gingivalis*, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer’s patients observed across multiple studies to date. Additionally, we have observed that *P. gingivalis* infection causes Alzheimer’s pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies. Our proprietary lead drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain protease inhibitor. COR388 was well-tolerated with no concerning safety signals in our Phase 1a and Phase 1b clinical trials conducted to date, which enrolled a total of 67 subjects, including nine patients with mild to moderate Alzheimer’s disease. We initiated a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in mild to moderate Alzheimer’s patients in April 2019 and expect top-line results by the end of 2021.

### Components of Results of Operations

#### Operating Expenses

##### Research and Development Expenses

Our research and development expenses consist of expenses incurred in connection with the research and development of our research programs. These expenses include payroll and personnel expenses, including stock-based compensation, for our research and product development employees, laboratory supplies, product licenses, consulting costs, contract research, preclinical and clinical expenses, and depreciation. We expense both internal and external research and development costs as they are incurred. Non-refundable advance payments and deposits for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as an expense as the related services are performed.

To date, substantially all of our research and development expenses have supported the advancement of COR388 and our other drug candidates are in early-stage preclinical development. As a result, we do not allocate our costs to individual drug candidates. We expect that at least for the foreseeable future, a substantial majority of our research and development expense will support the clinical and regulatory development of COR388.

We expect our research and development expenses to increase substantially during the next few years as we seek to complete existing and initiate additional clinical trials, pursue regulatory approval of COR388 and advance other drug candidates into preclinical and clinical development. Over the next few years, we expect our preclinical, clinical and contract manufacturing expenses to increase significantly relative to what we have incurred to date. Predicting the timing or the final cost to complete our clinical program or validation of our manufacturing and supply processes is difficult and delays may occur because of many factors.

We initiated a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in mild to moderate Alzheimer's patients in April 2019 and expect top-line results by the end of 2021. The duration, costs and timing of our clinical trial and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:

- per patient trial costs;
- biomarker analysis costs;
- the cost and timing of drug manufacturing for the trials;
- the number of patients that participate in the trials;
- the number of sites included in the trials;
- the countries in which the trials are conducted;
- the length of time required to enroll eligible patients;
- the drop-out or discontinuation rates of patients;
- potential additional safety monitoring or other studies requested by regulatory agencies; and
- the efficacy and safety profile of the product candidates.

Because our product candidate is still in clinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidate or whether, or when, we may achieve profitability.

#### *General and Administrative*

General and administrative expenses consist principally of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development, and other administrative functions, professional fees for legal, consulting, and accounting services, rent and other facilities costs, depreciation, and other general operating expenses not otherwise classified as research and development expenses.

We anticipate that our general and administrative expenses will increase substantially as a result of staff expansion and additional occupancy costs, as well as costs associated with being a public company, including higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs associated with being a public company.

#### *Interest Income*

Interest income consists of interest earned on our cash equivalents and investment gains and losses recognized during the period.

#### *Interest Expense*

Interest expense consists primarily of non-cash charges relating to expenses settled with the issuance of equity.

## Results of Operations

### Three Months Ended September 30, 2019 and 2018

The following sets forth our results of operations for the three months ended September 30, 2019 (in thousands):

	Three Months Ended September 30,		Change	
	2019	2018	\$	%
Operating expenses:				
Research and development	8,253	2,290	5,963	260.4 %
General and administrative	2,316	584	1,732	296.6 %
Loss from operations	(10,569)	(2,874)	(7,695)	267.7 %
Interest income	711	353	358	101.4 %
Net loss	(9,858)	(2,521)	(7,337)	291.0 %

### Research and Development Expenses (in thousands)

	Three Months Ended September 30,		Change	
	2019	2018	\$	%
Direct research and development expenses:				
COR388	5,729	1,284	\$ 4,445	346.2 %
Other direct research costs	589	299	290	97.0 %
Indirect research and development expenses:				
Personnel related (including stock-based compensation)	1,673	476	1,197	251.5 %
Facilities and other research and development expenses	262	231	31	13.4 %
Total research and development expenses	8,253	2,290	\$ 5,963	260.4 %

Research and development expenses were \$8.3 million for the three months ended September 30, 2019, compared to \$2.3 million for the three months ended September 30, 2018. The increase of \$6.0 million was driven mostly by increases of \$4.8 million in clinical trial expenses for our lead product candidate, COR388 which entered into Phase 2/3 clinical trials in 2019, \$0.3 million in drug manufacturing costs and \$0.2 million in non-clinical related costs. This was offset by a decrease of \$0.5 million in Phase I clinical trial expenses for COR388 incurring in 2018. Additionally, we experienced a net increase of \$1.2 million in personnel related expenses which was comprised of an increase in compensation and benefit costs of \$0.6 million and \$0.6 million in allocated stock-based compensation costs.

### General and Administrative Expenses

General and administrative expenses increased \$1.7 million, or 297%, from \$0.6 million for the three months ended September 30, 2018 to \$2.3 million for three months ended September 30, 2019. The increase in general and administrative expenses was primarily due to an increase of \$0.6 million in insurance costs and \$0.4 million in legal and accounting fees and other professional service fees associated with becoming a public company. In addition, personnel costs increased \$0.7 million due to an increase in our employee headcount and stock-based compensation expense related to those employees.

### Interest Income

Interest income was \$0.7 million for the three months ended September 30, 2019 compared to \$0.4 million for the three months ended September 30, 2018. The increase was a result of increased average cash and investment balances from the proceeds of our initial public offering which closed in May 2019.

## Nine Months Ended September 30, 2019 and 2018

The following sets forth our results of operations for the nine months ended September 30, 2019 (in thousands):

	Nine Months Ended September 30,		Change	
	2019	2018	\$	%
Operating expenses:				
Research and development	\$ 20,187	\$ 6,989	\$ 13,198	188.8 %
General and administrative	6,032	1,288	4,744	368.3 %
Loss from operations	(26,219)	(8,277)	(17,942)	216.8 %
Interest income	1,618	434	1,184	272.8 %
Interest expense	—	(957)	957	(100.0) %
Changes in fair value of derivative liability	—	(206)	206	(100.0) %
Net loss	\$ (24,601)	\$ (9,006)	\$ (15,595)	173.2 %

### Research and Development Expenses (in thousands)

	Nine Months Ended September 30,		Change	
	2019	2018	\$	%
Direct research and development expenses:				
COR388	\$ 15,605	4,265	\$ 11,340	265.9 %
Other direct research costs	1,052	562	490	87.2 %
Indirect research and development expenses:				
Personnel related (including stock-based compensation)	2,868	1,497	1,371	91.6 %
Facilities and other research and development expenses	662	665	(3)	(0.5) %
Total research and development expenses	\$ 20,187	\$ 6,989	\$ 13,198	188.8 %

Research and development expenses were \$20.2 million for the nine months ended September 30, 2019, compared to \$7.0 million for the nine months ended September 30, 2018. The increase of \$13.2 million was driven mostly by a \$11.4 million increase in clinical trial expenses for our lead product candidate, COR388, which entered into Phase 2/3 clinical trials in 2019, an increase of \$2.5 million in drug manufacturing and an increase of \$0.2 million in non-clinical related costs. This was offset by a decrease of \$2.3 million in Phase I clinical trial expenses for COR388 incurred in 2018. We experienced a net increase of \$1.4 million in personnel related expenses which was comprised of an increase in compensation and benefit costs of \$1.0 million, an increase of \$0.8 million in stock-based compensation offset by a decrease of \$0.4 million in payroll taxes related to refundable research and development payroll tax credits recorded in the first quarter of 2019.

### General and Administrative Expenses

General and administrative expenses increased \$4.7 million, or 369%, from \$1.3 million for the nine months ended September 30, 2018 to \$6.0 million for nine months ended September 30, 2019. The increase in general and administrative expenses was primarily due to an increase of \$1.6 million in personnel costs as a result of an increase in our employee headcount and an increase of \$3.1 million in insurance, legal, accounting fees and other professional service fees associated with becoming a public company.

### Interest Income

Interest income increased \$1.2 million from \$0.4 million for the nine months ended September 30, 2018 to \$1.6 million for the nine months ended September 30, 2019. The increase was a result of increased average cash balances from the proceeds of our initial public offering which closed in May 2019.

### Interest Expense

Interest expense decreased \$1.0 million for the periods presented. The decrease was due to the conversion of all of our outstanding convertible notes payable including accrued interest to preferred stock in May 2018 in connection with the Company's Series B Preferred stock financing.

## Liquidity, Capital Resources and Plan of Operations

We have incurred cumulative net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of September 30, 2019, we had an accumulated deficit of \$57.4 million. As of September 30, 2019, we had cash, cash equivalents and short-term investments of \$120.5 million.

Based on our existing business plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our anticipated level of operations for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the Securities and Exchange Commission.

### Capital Resources

Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to our Phase 2/3 drug candidate, COR388, and other research efforts, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

Our product candidate is still in the early stages of clinical development and the outcome of these efforts is uncertain. Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans. We may also be required to sell or license to others rights to our drug candidate in certain territories or indications that we would prefer to develop and commercialize ourselves.

As noted earlier, the Company completed an initial public offering, or the IPO in May 2019 by issuing and selling 5,073,800 shares of common stock at a public offering price of \$17.00 per share, including 661,800 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts and commissions and offering expenses, was approximately \$77.8 million. Upon the closing of the IPO, all of the outstanding shares of redeemable convertible preferred stock automatically converted into 18,161,027 shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.

### Cash Flows

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):

	Nine Months Ended September 30,	
	2019	2018
Net cash (used in) provided by:		
Operating Activities	\$ (22,327)	\$ (7,722)
Investing Activities	(35,451)	(48,315)
Financing Activities	77,896	75,938
Net increase in cash and cash equivalents	\$ 20,118	\$ 19,901

### Operating Activities

Net cash used in operating activities was \$22.3 million for the nine months ended September 30, 2019. Cash used in operating activities in the nine months ended September 30, 2019 was primarily due to our net loss of \$24.6 million for the period, and also due to use of cash in for prepaid expenses and other assets of \$3.5 million offset by cash provided by increases in our accounts payable and accrued expenses of \$4.7 million related to the activities surrounding our Phase 2/3 clinical trial. Non-cash operating income and expenses (net) accounted for \$1.1 million of the net loss.

Net cash used in operating activities was \$7.7 million for the nine months ended September 30, 2018. Cash used in operating activities in the nine months ended September 30, 2018 was primarily due to our net loss for the period of \$9.0 million. Non-cash operating income and expenses (net) accounted for \$1.2 million of the net loss.

### ***Investing Activities***

Cash used by investing activities was \$35.5 million in the nine months ended September 30, 2019, primarily related to the purchase of available for sale investment securities of \$98.5 million and maturities of \$63.0 million. Cash used by investing activities was \$48.3 million in the nine months ended September 30, 2018, primarily related to purchase of available for sale investment securities of \$48.1 million and property and equipment of \$0.2 million.

### ***Financing Activities***

Cash provided by financing activities was \$77.9 million in the nine months ended September 30, 2019, which consisted primarily of net proceeds from the initial public offering in the period.

Cash provided by financing activities was \$76.0 million in the nine months ended September 30, 2018, which consisted of net proceeds from the Company's Series B redeemable convertible preferred stock financing and the issuance of convertible promissory notes payable.

### **Contractual Obligations and Commitments**

#### ***Commitments***

There have been no material changes to our contractual obligations and other commitments as of September 30, 2019, as compared to those disclosed in our Prospectus.

We enter into contracts in the normal course of business with third party contract organizations for clinical trials, non-clinical studies and testing, manufacturing, and other services and products for operating purposes. The amount and timing of the payments under these contracts varies based upon the timing of the services.

#### **Off-Balance Sheet Arrangements**

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the rules and regulations of the SEC.

#### **JOBS Act**

As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley.

We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the consummation of our IPO, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least \$1.07 billion, (iii) the last day of the fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded \$700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than \$1.0 billion in non-convertible debt securities during the prior three-year period.

## **Critical Accounting Policies and Significant Judgments and Estimates**

Our management's discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the assumptions and estimates associated with accrued research and development expenditures and stock-based compensation have the most significant impact on our condensed financial statements. Therefore, we consider these to be our critical accounting policies and estimates.

There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled "Management's Discussion and Analysis of Financial Condition and Operations" included in our Prospectus.

## **Recent Accounting Pronouncements**

Please refer to Note 2 to our unaudited condensed financial statements appearing under Part 1, Item 1 of this report for a discussion of new accounting standards updates that may impact us.

## **Available information**

Our corporate website address is [www.cortexyme.com](http://www.cortexyme.com). We use the investor relations page of our website for purposes of compliance with Regulation FD and as a routine channel for distribution of important information, including news releases, analyst presentations, financial information and corporate governance practices. Our filings with the SEC are posted on our website and available free of charge as soon as reasonably practical after they are electronically filed with, or furnished to, the SEC. The SEC's website, [www.sec.gov](http://www.sec.gov), contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. The content on any website referred to in this Quarterly Report on Form 10-Q is not incorporated by reference in this Form 10-Q unless expressly noted. Further, the Company's references to website URLs are intended to be inactive textual references only.

## **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

### ***Interest Rate Risk***

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, invested in compliance with our policy.

We had cash, cash equivalents, and marketable securities of \$127.8 million as of September 30, 2019, which consisted primarily of bank deposits, money market funds, short-term and long-term marketable securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the short-term maturities of our cash equivalents and marketable securities, and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities.

We do not believe that inflation, interest rate changes, or exchange rate fluctuations had a significant impact on our results of operations for the three and nine months ended September 30, 2019.

## **Item 4. Controls and Procedures.**

### ***Evaluation of Disclosure Controls and Procedures***

Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended or the Exchange Act, is recorded, communicated to our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC's rules and forms.

Under the supervision and with the participation of our management, including the Chief Executive Officer or CEO and Chief Financial Officer or CFO, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2019. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting at December 31, 2018, which we view as an integral part of our disclosure controls and procedures, discussed in further detail below.

### ***Management's Report on Internal Control Over Financial Reporting***

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a15(f).

We identified the following material weaknesses at December 31, 2018:

Through December 31, 2018, we had not deployed adequate qualified resources in our corporate accounting department which resulted in material audit adjustments that were needed to modify the financial statements to comply with accounting principles generally accepted in the United States. Certain transactions were not adequately analyzed for accounting ramifications and accounting records contained errors and inaccuracies.

A plan to remediate the internal control deficiencies was implemented during the first quarter. We have hired and retained additional financial reporting personnel and are developing and implementing appropriate internal controls and reporting procedures. These remediation efforts continued during the three months ended September 30, 2019 and are expected to be completed during the year ending December 31, 2019.

However, we cannot assure you that these efforts will be effective in timely remediating the material weakness or that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations, which in turn could cause the trading price of our common stock to decline.

### ***Inherent Limitations on Effectiveness of Controls***

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure system are met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### ***Changes in Internal Control over Financial Reporting***

Other than the changes discussed above, there have been no changes in our internal control over financial reporting during the quarter ended September 30, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



**Item 1. Legal Proceedings.**

We are not currently a party to any material legal proceedings.

**Item 1A. Risk Factors.**

There have been no material changes to the risk factors previously disclosed by us in our Prospectus filed by us with the SEC on May 9, 2019. The risk factors included in our Prospectus continue to apply to us, and describe risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this Quarterly Report on Form 10-Q.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

**Unregistered Sales of Equity Securities**

None.

**Use of Proceeds**

On May 8, 2019, our registration statement on Form S-1 (File No. 333-230853) was declared effective by the SEC for our IPO. At the closing of the offering on May 13, 2019, we sold 5,073,800 shares of common stock, which included the exercise in full by the underwriters of their option to purchase additional shares, at an IPO price of \$17.00 per share and received gross proceeds of \$86.3 million, which resulted in net proceeds to us of approximately \$77.8 million, after deducting underwriting discounts and commissions of approximately \$6.0 million and offering-related transaction costs of approximately \$2.5 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. Merrill Lynch, Pierce, Fenner & Smith Incorporated and Credit Suisse Securities (USA) LLC. acted as joint book-running managers for the offering.

There has been no material change in the planned use of proceeds from our IPO from that described in the Prospectus filed by us with the SEC on May 9, 2019.

**Issuer Repurchases of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities.**

Not Applicable.

**Item 4. Mine Safety Disclosures.**

Not Applicable.

**Item 5. Other Information.**

None.

**Item 6. Exhibits.**

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

Exhibit Number	Description	Incorporated by Reference			Filed Herewith
		Form	Date	Number	
31.1*	<a href="#">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302crtx-ex311_8.htm of the Sarbanes-Oxley Act of 2002.</a>				X
31.2*	<a href="#">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				X
32.1*	<a href="#">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				X
32.2*	<a href="#">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				X
101.INS	XBRL Instance Document				X
101.SCH	XBRL Taxonomy Extension Schema Document				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document				X

\* This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cortexyme, Inc.

Date: November 12, 2019

By: /s/ Casey C. Lynch

Casey C. Lynch  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: November 12, 2019

By: /s/ Christopher Lowe

Christopher Lowe  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO  
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Casey C. Lynch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cortexyme, Inc. for the quarter ended September 30, 2019;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Casey C. Lynch

\_\_\_\_\_  
Casey C. Lynch  
President and Chief Executive Officer

Date: November 12, 2019

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO  
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Christopher Lowe, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cortexyme, Inc. for the quarter ended September 30, 2019;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Christopher Lowe

---

Christopher Lowe  
Chief Financial Officer

Date: November 12, 2019

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Cortexyme, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 12, 2019

By: \_\_\_\_\_ /s/ Casey C. Lynch  
**Casey C. Lynch**  
**Chief Executive Officer**

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Cortexyme, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 12, 2019

By: \_\_\_\_\_ /s/ Christopher Lowe

**Christopher Lowe**  
**Chief Financial Officer**